John M Leonard

CIK 1563584 · President and CEO · last filed 2026-08-24

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$51.02M

Companies

Total Filings

Lifetime Open-Market Net

-$60.76M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

NTLA price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest

OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address

C/O INTELLIA THERAPEUTICS INC
40 ERIE STREET, SUITE 130
CAMBRIDGE, MA 02139

Formerly Known As

LEONARD JOHN M. (2012–2020)

Related Filers

AbbVie Inc. — 6 joint filings, latest 2013-03-19

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
NTLA	President and CEO	1,208,264	$11.10	$13.41M	-$54.97M	39	2026-08-24
IQV	Director	16,946	$276.16	$4.68M	-$3.09M	10	2026-04-27
CHIMERIX INC (CMRX) Delisted	Director	4,000	$8.54	$34.2K	$138.2K	6	2017-06-29
Q	Director	4,702	$108.68	$511.0K	$0	4	2017-05-25
Vitae Pharmaceuticals, Inc (VTAE) Delisted	Director	—	—	—	$0	3	2016-10-25
ABBV	SVP, Chief Scientific Officer	113,793	$284.94	$32.42M	-$2.84M	5	2013-03-19

Recent Filings · Page 7 of 7

69 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2015-06-24	CHIMERIX INC (CMRX) Delisted	Grant (A)	—	$0	EDGAR
2015-05-08	Q	Grant (A)	+771	$0	EDGAR
2015-03-06	Q	Grant (A)	+770	$0	EDGAR
2014-11-06	CHIMERIX INC (CMRX) Delisted	Buy (P)	+4,000	$116.0K	EDGAR
2013-03-19	ABBV	Mixed	—	-$447.7K	EDGAR
2013-03-12	ABBV	Sell (S)	−27,949	-$1.05M	EDGAR
2013-03-04	ABBV	Tax (F)	−9,407	-$345.5K	EDGAR
2013-02-21	ABBV	Mixed	+4,305	-$143.2K	EDGAR
2013-02-19	ABBV	Mixed	+22,378	-$300.0K	EDGAR

Showing 61–69 of 69

Prev Page 7 of 7

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.